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Abstract
Introduction: This article describes the method development approaches for bioassay of substances containing un­
stable functional groups and forming unstable metabolites using the example of mycophenolic acid, methyldopa and 
mebeverine metabolites.
Materials and Methods: The concentration of mycophenolic acid, which contains one phenolic hydroxyl and forms 
glucuronides during metabolism, was measured in plasma using HPLC-MS/MS, HPLC-MS and GC-MS. The deter­
mination of methyldopa, containing two phenolic hydroxyls, in stabilised plasma was performed by HPLC-MS/MS in 
the range of 0.02-3.00 gg/ml. Desmethyl mebeverine acid, which contains one phenolic hydroxyl and is metabolised 
by forming phenolic glucuronide, was assayed simultaneously with mebeverine acid in the range of 10-2000 ng/ml.
Results and Discussion: The selection of storage conditions of the samples containing unstable substances should 
begin with selecting an anticoagulant based on the study of its short-term stability and freeze/thaw stability. If an un­
acceptable result is obtained, a combination of the anticoagulant and a stabiliser solution, as well as a concentration of 
this solution and its volume ratio to the biological fluid should be titrated. After which, this method should be validated 
by using the selected anticoagulant or the combination of the anticoagulant and stabiliser solution.
Conclusion: The application of this approach to developing a bioanalytical method for determination of unstable com­
pounds makes it possible to avoid obtaining false assay results.
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Introduction
Stability of the analytes in biological matrices is an im­
portant component, which guarantees obtaining reliable 
results of bioanalytical studies. Thus, a wrong conclusion 
about the bioequivalence (BE) of the generic and original 
drug can lead to the registration of the drug which does
not meet the requirements of effectiveness and safety. Er­
rors of therapeutic drug monitoring may result in a faulty 
dosage (Khokhlov 2017), which puts patients’ health at 
high risk.
Oxidation and hydrolysis are the main causes for the 
decomposition of molecules of drugs and their metaboli­
tes in biological fluids (Khokhlov 2017, Yaichkov et al.
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2017, Dell 2004, Khokhlov et al. 2017a, Hilhorst et al. 
2017, Li et al. 2013, Li et al. 2011). Stabilisation of bio­
logical samples may be achieved by changing the storage 
conditions, selecting an anticoagulant and adding stabi­
lisers depending on the structure of the analyte: antioxi­
dants, buffer solutions, acid solutions and bases for pH 
correction, enzyme inhibitors (Yaichkov et al. 2017, Dell 
2004, Khokhlov et al. 2017a, Hilhorst et al. 2017, Li et al. 
2013, Li et al. 2011). Substances which contain phenolic 
hydroxyls are the main examples of readily oxidisable 
compounds (Khokhlov et al. 2017a, Hilhorst et al. 2017). 
Back conversion of glucurone conjugates into the parent 
drugs is the most common example of the hydrolysis 
of compounds in biological fluids (Hilhorst et al. 2017, 
Li et al. 2011). Thus, over the last 5 years, results have 
been published for over 30 bioanalytical studies of drugs 
which metabolise by forming glucuronides (Yaichkov et 
al. 2017, Li et al. 2011, Brntas et al. 2016, Veeragoni et al. 
2016, Shah et al. 2016, Sengupta et al. 2017, Patel et al. 
2017). The least stable are О-acylglucuronides (Yaichkov 
et al. 2017, Dell 2004, Hilhorst et al. 2017, Li et al. 2013, 
Li et al. 2011); however, phenolic glucuronides may also 
undergo hydrolytic decomposition (Li et al. 2011, Ye et 
al. 2017).
Therefore, mycophenolic acid (MPA) and desmethyl 
mebeverine acid (DMA) which both contain one pheno­
lic hydroxyl and methyldopa (MD) which contains two 
phenolic hydroxyls (Fig. 1) were selected to develop ap­
proaches to bioassay of substances containing unstable 
functional groups.
Besides, MPA and DMA are conjugated to glucuron- 
ides during metabolism (Khokhlov 2017, Kristinsson et 
al. 1994, Khokhlov et al. 2016), which results in MPA 
forming acylglucuronide (AcMPAG) and phenolic glucu- 
ronide (MPAG) with DMA forming only phenolic glu- 
curonide (DMAG). A literature review showed that there 
was no need to add antioxidant solutions to the samples 
of biological fluids (Khokhlov et al. 2016, Benoit-Bian- 
camano et al. 2007, Brandhorst et al. 2016, Heinig et al. 
2010, Oliveira et al. 2002, Rуna et al. 2001, Vlase et al. 
2013, Valizadeh et al. 2010, Elliott and Burgess 2006). 
The results of studying back-conversion of MPAG and 
AcMPAG during the storage process differ: some authors 
emphasise the necessity to use buffer solutions to slow 
hydrolysis of these metabolites (Benoit-Biancamano et 
al. 2007, Brandhorst et al. 2016), whereas others state 
that degradation of MPA conjugates was not significant 
and adding stabilisers was not necessary (Khokhlov et al. 
2016, Heinig et al. 2010). Therefore, studying this pro­
cess is of current concern.
Materials and Methods
Sample preparation for HPLC-MS/MS-determination of 
MPA was performed using deproteinisation: 450 pl of the 
deuterated internal standard (IS) methanol solution of 
mycophenolic acid-D3 was added to 50 pl of plasma. The 
mixture was vortexed and centrifuged at 2500 rpm for 10 
min. A Kinetex C18 column (30 * 4.6 mm, 2.6 pm) with
Figure 1. Graphic formulae of mycophenolic acid (А), methyldopa (B) and desmethyl mebeverine acid (C).
a Phenomenex Security guard (C18, 4 * 3 mm) and a mo­
bile phase based on acetonitrile and water in the gradient 
elution mode were applied for the analysis. Mass spec­
trometry detection was carried out in negative ion MRM 
mode by the following MRM-transitions: MPA -  319 ^  
191+205 m/z; MPA-D3 -  322 ^  191 + 205 m/z (Khok­
hlov et al. 2016).
Protein precipitation was also used for preparing the 
samples for HPLC-MS-determination of MPA: 50 pl of 
plasma was vortexed with 200 pl of methanol. The mix­
ture was centrifuged at 10000 rpm for 5 min. Separation 
was conducted on a Zorbax Eclipse Plus C18 column 
(100 * 4.6 mm, 3.5 pm) using a mobile phase based on 
acetonitrile, water and a 0.1% solution of formic acid
(50:45:5, v/v/v) in the isocratic elution mode. Negative 
ions of MPA were detected in the SIM-mode by molecu­
lar ion -  319 m/z (Khokhlov et al. 2017a).
Liquid-liquid extraction by methylene chloride after 
correcting the pH value to 2.0 by phosphate buffer solution 
was used for preparing plasma samples for GC-MS-deter- 
mination of MPA. After separation and evaporation of the 
extract, derivatisation of the analyte by a mixture of N,O- 
bis (trimethylsilyl)-trifluoroacetamide and trimethylchlo- 
rosilane was performed. Chromatographic separation was 
done using Mega 5-MS column (25 m * 0.20 mm, 0.33 
pm) under the following temperature programme: the in­
itial temperature was 100°C for 3 min, heating was done 
at a rate of 25°C/min up to 300еС, the final temperature
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was 300еС for 8 min (the total run time - 19 min). Mass 
spectrometric detection of di-TMS-derivative of MPA 
was performed in the SIM-mode -  449 m/z.
The method of HPLC-MS/MS was used to measure the 
concentration of DMA and a minor mebeverine metabo­
lite -  mebeverine acid (МА) in plasma. The samples were 
prepared by protein precipitation. A methanol solution 
(400 pl) of deuterated standards of mebeverine acid-D5 
(MA-D5) and desmethyl mebeverine acid-D5 (DMA-D5) 
was added to an aliquot of plasma of 100 pl. The mixture 
was centrifuged at 3500 rpm for 10 min after vortexing. 
Chromatographic separation was performed on two col­
umns Luna C8 Mercury (20*4.0 mm, 5 pm) and Luna 
5u C8 (150*4.6 mm, 5 pm) using a mobile phase based 
on acetonitrile, methanol and formate buffer solution in 
the gradient elution mode. Mass spectrometry detection 
was carried out in positive ion registration mode by the 
following MRM-transitions: MA -  280—121 m/z, DMA 
-  266— 107 m/z, MA-D5 -  285—121 m/z and DMA-D5 -  
271— 107 m/z (Khokhlov et al. 2017a).
The samples containing methyldopa for HPLC-MS/ 
MS determination of its concentration were prepared 
by protein precipitation. First, 400 pl of deuterated in­
ternal standard of methyldopa-D3 (MD-D3) in methanol 
was added to 100 pl of plasma; then the mixture was 
vortexed and centrifuged at 3500 rpm and temperature 
of +4°С for 10 min. Chromatographic separation of the 
sample components was done using two columns Luna 
Phenyl-Hexyl (50*3.0 mm, 5 pm) and Synergi Fusion RP 
80Е (150*3.0 mm, 4 pm) in the isocratic elution mode. 
Mass spectrometry detection was carried out in positive 
ion registration mode by the following MRM-transitions: 
for MD -  212—^ 139 m/z; for MD-D3 (IS) 215— 169 m/z 
(Khokhlov et al. 2017c).
Results and Discussion
At the beginning of developing the methods for de­
termining MPA using HPLC-MS and HPLC-MS/MS, 
back-conversion of MPAG in the ion source was investi­
gated. The selected chromatographic parameters for both 
methods allow separating the analyte and its main meta­
bolite (Figs. 2 and 3); that is the reason why its fragmen­
tation in the ionisation process does not affect the accu­
racy of measuring MPA. This experiment was not carried 
out when using the GC-MS method, because MPAG is 
not recovered from the plasma under the selected extrac­
tion conditions.
A preliminary evaluation of the stability of mycopheno- 
lic acid was made by applying the HPLC-MS/MS method 
in plasma samples at a concentration of 25.0 pg/ml using 
K3EDTA and lithium heparinate as anticoagulants. The re­
sults obtained after 24 h of keeping the model mixtures 
at room temperature and 3 freeze/thaw cycles meet the 
acceptance criteria: mean concentration values of MPA at 
K3EDTA were 99.8% and 100.6% of the initial concen­
tration, respectively and at lithium heparinate-plasma they 
were 101.1% and 97.2% of the initial concentration, res­
pectively. Thus, mycophenolic acid containing one pheno­
lic hydroxyl is resistant to oxidation in blood plasma.
Back-conversion of MPAG during the storage process 
was also studied using these anticoagulants on the sam­
ples at a concentration of this metabolite of 100 pg/ml 
(Khokhlov et al. 2016). If the lower limit of quantification 
(LLOQ) of the method is 0.05 pg/ml, MPAG hydroly­
sis exceeds the maximum permissible level (20% of the 
MPA chromatographic peak area of the LLOQ sample) 
after 6 hours of storage at room temperature using K3ED- 
TA, which is significantly higher than with using lithium 
heparinate (Table 1). If LLOQ of the method is 0.5 pg/ 
ml, back-conversion of MPAG is at the acceptable level 
when applying both anticoagulants. The LLOQ level of 
0.5 pg/ml is sufficient for conducting of BE studies of 
mycophenolic acid formulations (Khokhlov et al. 2016). 
However, when using lithium heparinate, the hydrolysis 
degree of the metabolite was approximately three times 
higher. That is the reason why K3EDTA was selected for 
further studies (Table 1).
The absence of influence of back-conversion of AcM- 
PAG and MPAG on the accuracy of mycophenolic acid 
determination was also proved by re-analysis of the plas­
ma samples obtained from rats for cross-validation. The 
difference between the initial and final results of measu­
rements ranged from -3.43% to 9.49%, which does not 
exceed the maximum acceptable value of 20% (European 
Medicines Agency 2010, Mironov 2014, Council of the 
Eurasian Economic Commission 2016).
When developing a method for determining mebeve- 
rine metabolites in plasma, fragmentation of DMAG in 
the ionisation process was also studied. There was no de­
composition of this metabolite in the ion source (Fig. 4).
The results of testing the stability of desmethyl mebe- 
verine acid, containing one phenolic hydroxyl, in plasma 
after 24 hours by maintaining samples at room tempera­
ture and 3 freeze/thaw cycles, met the acceptance criteria. 
Back-conversion of DMAG in the samples with a con­
centration of 2000 ng/ml kept for 24 hours at room tem-
Table 1. Study of Back-Conversion of Phenolic Glucuronide of Mycophenolic Acid During Storage.
% of the chrom. peak area of LLOQ sample 
LLOQ of the method 0,5 pg/ml LLOQ of the method 0,05 pg/ml
________________________________ K3EDTA_______Lithium heparinate_______ K3EDTA_______ Lithium heparinate
Storage time, h 2 h - - 6.0 23.9
(room temperature) 6 h - - 17.0 75.2
24 h 2.58 7.44 45.2 154.3
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Figure 2. MRM-chromatogram of the mixture of MPA and 
MPAG when using HPLC-MS/MS method.
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Figure 3. Chromatograms of MPA (А) and MPAG (B) solutions 
when using HPLC-MS method.
perature was completely absent. Consequently, addition 
of the stabiliser solution to the K3EDTA plasma in this 
case is not required.
A preliminary study of the short-term stability and free- 
ze/thaw stability of methyldopa, containing two phenolic 
hydroxyls, was carried out on plasma model mixtures at a 
concentration of 2.40 pg/ml. K3EDTA and lithium hepa- 
rinate were used as anticoagulants. The obtained results 
did not meet the acceptance criteria (Table 2). Therefore, 
it was necessary to add an antioxidant solution to the plas­
ma to prevent oxidation of the analyte. The usage of solu­
tions of ascorbic acid at a concentration of 5 and 10% and 
a solution containing a mixture of ascorbic acid, sodium 
sulphite and sodium bicarbonate at concentrations of 5%, 
0.2% and 2.4%, respectively, used with K3EDTA in the 
ratio of 1:5 (antioxidant solution/plasma), made it pos­
sible to prevent degradation of the substance (Table 2). 
The mixture of ascorbic acid, sodium sulphite and sodi­
um bicarbonate was selected for further studies, because
the sensitivity of the method was highest when using this 
mixture (Khokhlov et al. 2017a, Khokhlov et al. 2017c).
Thus, addition of an antioxidant stabiliser was neces­
sary only when studying methyldopa, which contains two 
phenolic hydroxyls. The DMA molecule remained sta­
ble in plasma, despite the absence in the benzene ring of 
electron-withdrawing groups, which reduce the electron 
density and, thus, oxidation capacity. Back-conversion 
of the phenolic glucuronide of DMA was also comple­
tely absent. Hydrolysis of MPA conjugates, when using 
K3EDTA as an anticoagulant, was at an acceptable level, 
which made it possible to avoid using buffer solutions to 
correct the pH of the medium.
Validation of the developed methods
The developed methods were validated in accordance 
with the requirements of EMA Guidelines (European 
Medicines Agency 2010), The Guidelines on the Eva-
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Table 2. Selection of Stabilisers to Prevent Oxidation of Methyldopa.
Stabiliser
Short-term 
stability (24 
h at room 
temperature), 
n=2
Freeze/ thaw 
stability 
n=2
Short-term 
stability (24 
h at room 
temperature), 
n=2
Freeze/ thaw 
stability 
n=2
Concentration of %  of initial concentration
stabiliser, % K3EDTA Lithium heparinate
Without stabiliser - 30.29 80.04 47.16 93.18
Ascorbic acid 5 88.44 102.30 80.91 99.69
10 94.91 96.17 78.76 93.21
Mixture of ascorbic acid, 5% ascorbic acid, 0.2%
sodium bicarbonate, sodium sulphite, 2.4% 89.31 98.24 72.48 95.07
sodium sulphite sodium bicarbonate
Sodium thiosulphate 5 45.65 101.86 79.41 93.91
10 31.32 99.81 83.46 97.78
Sodium metabisulphite 5 66.84 102.68 75.79 90.70
10 75.99 97.25 73.22 88.70
luation of Medicinal Products by The Scientific Cent­
re for Expert Evaluation of Medicinal Products of the 
Ministry of Healthcare of the Russian Federation (Vol. 
1) (Mironov 2014) and Decision of the Council of the 
Eurasian Economic Commission № 85 “On Approval 
of the Rules for Conducting Bioequivalence Studies on 
Medicines in the Eurasian Economic Union” (Council 
of the Eurasian Economic Commission 2016). The re­
sults of validation tests meet all the acceptance criteria 
(Table 3).
Thus, the selected anticoagulants (for MPA and DMA) 
and the combination of an anticoagulant with a stabili­
ser solution (for MD) provide stability of the analytes in 
plasma samples for 24 hours at room temperature, 3 free- 
ze/ thaw cycles and under freezing conditions (Table 4). 
The usage of a storage temperature not higher than -80°C 
made it possible to increase the storage period of samples 
containing methyldopa by up to 3 months.
Application of the developed methods
The HPLC-MS/MS method of MPA determination was 
applied for conducting a bioequivalence study of coated 
tablets of mycophenolate sodium (Khokhlov et al. 2016). 
The HPLC-MS and G C^S-m ethods of quantification of 
mycophenolic acid were tested by cross validation in rat 
plasma samples. The method developed for measuring 
MD concentrations in plasma was used in an open rando­
mised cross-over study of bioequivalence of methyldopa 
tablet formulations (Khokhlov et al. 2017a). The method 
of determining MA and DMA in plasma was applied to 
conduct a pharmacokinetics study of mebeverine sustain­
ed release capsules (Khokhlov et al. 2017b).
The statistical analysis was performed using StatSoft 
STATISTICA v.10, R package, Bear module (Lee, Hsin- 
ya and Lee, Yung-jin, bear: Data Analysis Tool for Aver­
age Bioequivalence and Bioavailability) and Microsoft 
Excel 2007.
Results of cross validation of methods for determining 
mycophenolic acid
The study was carried out on 10 white mongrel male rats 
weighing 250±10 g in accordance with the principles of 
Good Laboratory Practice (Ministry of Healthcare of the 
Russian Federation 2016). The aqueous solution of my­
cophenolate sodium was administered to rats orally in the 
dosage of 33.0 mg/kg. Blood sampling was performed 2 h 
after administration, as it is the time of MPAG and AcM- 
PAG peak concentrations in plasma (Liu et al. 2017). Part 
of the plasma obtained after centrifusion was subjected to 
immediate sample preparation. The HPLC-MS/MS-me- 
thod was chosen as a reference method, because to calcu­
late the concentrations of MPA, a stable isotope-labelled 
internal standard MPA-D3 was used which is the most 
preferable in accordance with the Eurasian Economic 
Union Guidelines for conducting BE studies (Council of 
the Eurasian Economic Commission 2016).
The relative concentrations of MPA obtained by the 
HPLC-MS-method were within the range of 95.18­
106.93% compared to the HPLC-MS/MS results; con­
centrations obtained by the GC-MS-method were within 
the range of 94.27-110.26% (Table 5). It meets the accep­
tance criteria (European Medicines Agency 2010, Miron­
ov 2014, Council of the Eurasian Economic Commission 
2016): relative error does not exceed ± 20% for over 67% 
of samples. Thus, HPLC-MS and GC-MS methods de­
veloped for MPA determination provide accurate results 
without using a stable isotope-labelled internal standard 
for calculating the concentration.
Results of bioequivalence study of methyldopa tablet 
formulations
The study of comparative pharmacokinetics of methyldo- 
pa formulations was conducted on 24 healthy volunteers. 
The test drug was Methyldopa tablets (250 mg) (R-Pharm,
Table 3. Validation Results of Methods Developed. GO00
Mycophenolic acid Mebeverine metabolites (HPLC-MS/MS) Methyldopa (HPLC- 
MS/MS)Parameter HPLC-MS/MS HPLC-MS GC-MS Mebeverine acid Desmetyl mebeverine acid
Selectivity Interference in the retention times of analytes did not exceed 20% of the LLOQ level, in the retention times of internal standards (except for HPLC-MS and GC-MS methods of determining MPA) did not exceed 5% of the average peak area.
LLOQ 0.5 (.ig/ml 0.05 (.ig/ml 0.05 (.ig/ml 10 ng/ml 10 ng/ml 0.02 pg/ml
Calibration curve 0.5-30.0 (.ig/ml 0.05-30.00 pg/ml 0.05-30.00 (.ig/ml 10-2000 ng/ml 10-2000 ng/ml 0.02-3.00 (.ig/ml
Accuracy (relative error) -4.03 4+12.85%. -14.02% 4 +11.82% -14.35% 4 +6.82% -11.83% 4 +13.86% -1.73% 4 +13.77% -5.28% 4 +7.42%
Precision (CV, %) 1.72% ч8.52% 0.36% 4 9.82% 1.95% 4 5.58% 1.40% 4 8.24% 1.40%4 8.58% 0.69% 4 3.97%
Matrix effects LQC 7.46% 2.96% (MF) 2.28% (MF) 3.66% 1.59% 0.38%
(CVNMF) HQC 6.55% 5.60% (MF) 2.80% (MF) 5.47% 2.82% 1.45%
Dilution integrity (relative 
error)
-6.47% 4 +5.71% -9.46% 4 +4.22% -0.84% 4 +10.99% -2.04% 4 +1.88% +0.64% 4 +4.13% -1.94% 4 +3.27%
Note: LLOQ - lower limit of quantification, LQC- low QC samples; HQC - high QC samples; NMF -  normalised matrix factor; MF- matrix factor
Table 4. Stability Study of Analytes in Blood Plasma.
Mebeverine metabolites
Parameter Mycophenolic acid MA DMA Methyldopa
Short-term stability LQC 99.18 107.72 106.33 95.50
(24 h), % initial cone. HQC 99.46 97.81 98.54 89.58
Freeze/ thaw stability LQC 105.10 111.83 105.44 104.43
(3 cycles), % initial cone. HQC 103.55 102.45 102.79 106.95
Autosampler stability, LQC 107.72 109.06 103.44 101.91
% initial cone. HQC 108.07 97.44 94.96 101.28
Long-term not exceeding 
stability, % -20 °C
LQC 100.38 103.24 
(1 month) (4 months)
111.56 
(1 month)
109.33 
(4 months)
108.61 
(1 month)
105.83 
(4 months)
90.74 66.92 
(1 month) (3 months)
initial cone. HQC 94.79 100.86 
(1 month) (4 months)
105.45 
(1 month)
103.56 
(4 months)
110.33 
(1 month)
110.06 
(4 months)
86.20 59.57 
(1 month) (3 months)
not exceeding 
-80°C
LQC " " " " 100.60 (1 100.76(3 
month) months)
HQC " " " " 99.12 94.08 
(1 month) (3 months)
K
h
o
k
h
lo
v
 A
L
 e
t a
t: 
M
e
th
o
d
ica
l 
a
p
p
ro
a
c
h
e
s to
 b
io
a
ssa
y
 o
f 
su
b
sta
n
c
e
s c
o
n
ta
in
in
g
 u
n
sta
b
le
 fu
n
c
tio
n
a
l g
ro
u
p
s
Research Result: Pharmacology and Clinical Pharmacology 4(1): 33-42 39
Russia, batch number 20614, expiry date: 07.2016) and a 
reference preparation was Dopegit (Egis, Hungary, batch 
number D358N1014, expiry date: 10.2019). Blood sam­
ples was taken pre-dose and post-dose at 5 min, 15 min, 
30 min, 45 min, 1 h, 1 h 15 min, 1 h 30 min, 1 h 45 
min, 2 h, 2 h 15 min, 2 h 30 min, 3 h, 4 h, 6 h, 9 h, 12 h, 
18 h and 24 h after drug administration in vacuum tubes 
with K3EDTA. Then the blood samples were immediately 
centrifuged at a speed of 3000 rpm and a temperature of 
+4°C for 5 minutes. A stabiliser solution was added to the 
obtained plasma. A total of 864 samples were analysed 
using the developed method.
The values of the pharmacokinetic parameters of the 
drugs under study are not statistically significantly dif­
ferent (Table 6) and their average pharmacokinetic pro­
files practically coincide (Fig. 5). The calculated values 
of the 90%-confidence intervals of the parameters C , 
AUC , C /AUC are within the acceptable limits of 
80.0-125.0% (Table 7). The coefficient of intra-subject 
variability of C was 33.10%, which conformed to the 
level of a highly variable drug. The results of multivariate 
analysis of variance (ANOVA) show that the main factor 
contributing to the variability of this parameter was the
subjects themselves (p = 0.027). Incurred samples re-ana­
lysis (of 96 samples - 11.1% of the total amount) showed 
100% reproducibility of the analytical method.
Thus, Methyldopa (by R-Pharm, Russia) and Dopegit 
(by Egis, Hungary) are bioequivalent. The measures de­
veloped for stabilisation of the analyte ensure validity of 
the results obtained.
Results of the pharmacokinetic study of mebeverine 
sustained release capsules
The cohort for assessing pharmacokinetic parameters 
of MA and DMA after administration of sustained release 
capsules of Duspatalin (200 mg) (by Abbott Healthcare 
SAS, France, batch number 10215, expiry date: 04.17) in­
cluded 24 subjects aged 18-45 years. Blood samples were 
taken pre-dose and post-dose at 0.5 h, 1 h, 1.5 h, 2 h, 2.5 
h, 3 h, 3.5 h, 4 h, 5 h, 6 h, 8 h, 10 h, 12 h and 24 h after 
drug administration in vacuum tubes with K3EDTA. Then 
the plasma was immediately separated by centrifusion 
and frozen. A total of 360 samples were analysed.
Thus, the obtained data about the pharmacokinetic pa­
rameters of mebeverine metabolites after taking sustained 
release capsules can be used to develop a bioequivalence 
study design of studies (Table 8, Fig. 6)
Table 5. Cross Validation of Methods for Determining Mycophenolic Acid in Plasma.
№ of sample
Determinations 
by HPLC-MS/MS 
method
Determinations by HPLC-MS method Determinations by GC-MS-method
Abs. pg/ml Rel. % Abs. pg/ml Rel. %
1 9.82 9.35 95.18 9.63 98.11
2 8.65 8.96 103.55 8.16 94.27
3 5.64 5.18 91.86 5.57 98.80
4 9.61 9.66 100.58 10.38 108.01
5 12.36 12.31 99.62 11.86 95.94
6 9.02 9.01 99.81 9.57 105.99
7 4.63 4.95 106.93 4.62 99.82
8 20.09 21.40 106.54 19.60 97.54
9 9.18 9.65 105.05 10.01 109.00
10 7.44 7.89 106.10 8.20 110.26
Mean 101.77 - 101.52
Table 6. Main Pharmacokinetic Parameters of Test and Reference Methyldopa Drug.
Pharmacokinetic
parameters
Test drug 
(Mean± SD)
Reference drug 
(Mean± SD) Criteria of comparison P
C , ug/mlmax 1.227±0.601 1.233±0.419 Student’s t-test for dependent 0.952
AUCM, ug*h/ml 6.219±3.080 6.385±2.153 group 0.740
AUC0m, ug*h/ml 6.436±3.181 6.529±2.187 0.997
Cmax/AUC0-t, h-1 0.202±0.038 0.198 ±0.037 0.663
K ,, h4 0.229 ±0.110 0.207±0.107 0.127
Ts, h 3.89±2.13 4.45±2.37 0.056
MRT, h 4.97±0.77 4.98±0.76 1.000
Tmax, h 3.18±1.23 2.90±0.86 Wilcoxon signed-rank test 0.469
Note: C - maximum plasma concentration in blood; T - time-to-peak concentration; AUC„. - area under the pharmacokineticmax max 0-t
concentration-time curve from time zero to the last blood sampling procedure; AUC0 ю - area under the pharmacokinetic curve from 
time zero to infinity; Cmax/AUC01 - relative absorption rate; Kel - terminal elimination rate constant; Ts - drug elimination half-life; 
MRT - mean residence time.
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Figure 5. Averaged pharmacokinetic profiles of methyldopa 
concentrations in blood plasma after administration of test (T) 
and reference (R) drug.
concentrations in blood plasma after administering a single dose 
of Duspatalin (200 mg).
Table 7. Results of Comparison of Bioequivalence of Methyldopa formulations.
90% confidence intervals
Parameter
Geometric 
mean ratio
Estimated value Acceptable value Intra-subject 
variability coefficientLower limit Upper limit Lower limit Upper limit
AUC0-t 92.93% 80.69% 107.03% 80.00 125.00 29.08%
C 94.89% 80.88% 111.34% 80.00 125.00 33.10%
C /AUC 102.11% 93.95% 110.98% 80.00 125.00 16.92%
Table 8. Pharmacokinetic Parameters of Mebeverine Metabolites.
Mebeverine acid
C , ng/ml
m a x Tm a x , h AU^ng^h/ml
AUC.
0-a>,
ng^h/ml
a u c 0-i / 
AUCo ^  %
C /
m a x
AUC0 1, h-1 K . h-1 Т1 /2, h
MRT, h
Mean±SD 62.52± 3.27± 293.94± 365.85± 82.34± 0.2238± 0.27584± 2.87± 5.82±
35.01 1.03 151.78 140.49 11.61 0.0598 0.08426 1.39 1.57
Min 22.3 1.5 54.03 110.01 47.43 0.1649 0.08683 1.61 4.27
Max 173.5 5 601.03 649.49 96.04 0.4128 0.43138 7.98 11.45
CV % 56.00 31.55 51.64 38.40 14.10 26.72 30.55 48.38 26.91
Desmethyl mebeverine acid
C , ng/ml
m a x Tm a x , h
AUC0 - ,
ng^h/ml
AUC
0 - » ,
ng^h/ml
AUC0 - t/ 
AUCo ^  %
C /
m a x
AUC0 1, h-1 h-1 Т1 /2, h
MRT, h
Mean±SD 291.81± 3.19± 2191.85± 2551.74± 86.26± 0.1339± 0.11605± 7.52± 11.2±
125.92 1.48 542.94 546.96 11.62 0.0497 0.06657 3.31 4.25
Min 114.6 1.5 1081.45 1388.65 40.34 0.0838 0.04631 2.33 5.34
Max 607.4 8 3262.43 3547.35 95.84 0.2969 0.29771 14.97 22.49
CV % 43.15 46.44 24.77 21.43 13.47 37.15 57.36 44.04 37.97
Conclusions
The method for the quantitative determination of substan­
ces forming such metabolites as glucuronides, N-oxides, 
esters, lactones and also for the simultaneous analysis of 
esters and lactones with their acid forms should ensure 
that there is no influence of degradation of these com­
pounds in the ion source on the results of measuring the 
analyte concentration. The selection of storage conditions 
for samples containing substances with unstable functi­
onal groups should begin by selecting an anticoagulant, 
based on a study of short-term stability and freeze/thaw 
stability of the analyte and back-conversion of its meta­
bolites. When obtaining an unacceptable result, it is ne­
cessary to select a combination of an anticoagulant and a 
stabiliser solution, as well as a concentration of this so­
lution and its volume ratio to the biological fluid. After 
this, the developed method should be validated using the 
selected anticoagulant or a combination of the anticoagu­
lant and stabiliser solution.
Thus, the application of this approach to developing 
a bioanalytical method for determination of compounds 
containing unstable functional groups makes it possible 
to avoid obtaining false assay results. This significantly 
reduces the risk to the health of patients when administe­
ring generic drugs or when using the results of therapeu­
tic drug monitoring for correcting the dosage.
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